| 英文摘要 |
Current guidelines recommend statins as the first-line therapy in primary and secondary prevention of atherosclerotic cardiovascular diseases, but statins increase the incidence of new-onset diabetes mellitus. We explored whether pitavastatin, with a less diabetogenic effect, can improve glycemic control in patients with diabetes compared to other statins. We retrieved data from electronic medical records of out-patient clinics in two hospitals located in Southern Taiwan. Dyslipidemic patients with pitavastatin therapy were divided into the following three groups based on baseline fasting glucose levels: the diabetes group, the impaired fasting glycemia (IFG) group, and the normal group. In each group, statin-naïve patients were defined as those using pitavastatin as the first statin for lipid control without prior statin use. In contrast, patients with prior statin were those who received other statin originally and were switched to pitavastatin thereafter. We compared the difference between the baseline and 3-month glycated hemoglobin (HbA1C) levels in each group after initiating pitavastatin use. There was no obvious change in HbA1C in patients in the IFG and normal groups after 3 months of treatment with pitavastatin. On the other hand, patients in the diabetes group had significantly lower 3-month HbA1C after they received pitavastatin (baseline HbA1C: 7.66±1.42%; 3-month HbA1C: 7.52±1.38%, P = 0.027), especially among the statin-naïve patients. Compared to other high-intensity statins (HIS), pitavastatin had similar lipid-lowering efficacy. Our study suggests that pitavastatin may improve glycemic control in diabetic patients, especially among those without previous statin exposure. |
本站僅提供期刊文獻檢索。
